KEYLYNK-012
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
- NCT04380636 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on KEYLYNK-012 (pembrolizumab plus olaparib; pembrolizumab in unresectable stage III non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYLYNK-012 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab; Olaparib; Placebo for olaparib; Etoposide; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; Thoracic Radiotherapy; Durvalumab
- Arms
- pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo · Experimental
- pembrolizumab+chemoradiation→pembrolizumab+olaparib · Experimental
- chemoradiation→durvalumab · Active comparator
- Enrollment
- 870 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jul 6, 2020
- Primary completion
- May 5, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04380636 · updated May 15, 2026
Publications
linked from the registry- Jabbour SK, Cho BC, Bria E, Kato T, Bhosle J, Gainor JF, Reguart N, Wang L, Morgensztern D, Shentu Y, Kim SJ, Souza F, Reck M. Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 Sep;23(6):e342-e346. doi: 10.1016/j.cllc.2022.04.003. Epub 2022 Apr 29. PubMed 35618629